Drug price reporting bill would require notices

Summary#

Wisconsin SB 1149 would add new prescription-drug reporting rules to state law and provide funding for the Department of Health Services (DHS) to administer them. Its stated goal is drug-cost reporting; it does not require drug prices to fall. The bill failed, so these proposed rules and funding did not take effect.

  • Drug manufacturers would have to give DHS and the Office of the Commissioner of Insurance (OCI) advance notice of certain large price increases and high-priced drug introductions, with a written justification.
  • Manufacturers would also have to report price concessions to pharmacy benefit managers for drugs that triggered a notice, and report on manufacturer-sponsored assistance programs for drugs sold in Wisconsin.
  • DHS would have to publish the price justifications, analyze the reports, publish a report on drug-pricing trends, and hold at least one public hearing each year.
  • DHS would decide the forfeiture for a missed notice or report, up to $10,000 for each day it is late. Manufacturers would certify reports as accurate under penalty of perjury.
  • The bill would provide DHS $184,200 in each of fiscal years 2025–26 and 2026–27, and authorize two additional DHS positions.

What it means for you#

  • Drug manufacturers: The proposed notice rule would apply to a brand-name drug price increase of more than 25% over 24 months, or a generic drug increase of more than 25% or more than $300 during any 12-month period. Notice would also be required before introducing a brand-name drug with an annual wholesale acquisition cost of at least $30,000, or a generic drug at least $3,000. Notice and justification would be due at least 30 days before the planned increase or introduction.
  • Drug manufacturers: The justification would have to include documents and research related to the price decision, estimated cost-effectiveness, information about similar drugs and anticipated sales, and the impact of discounts to pharmacy benefit managers, insurers, and other health-care payers.
  • Drug manufacturers: By March 1 each year, they would report price concessions to each pharmacy benefit manager for each drug that triggered a notice. Manufacturers of any brand-name or generic drug sold in Wisconsin would also report on assistance programs, including participation criteria, terms, prescription counts, and the total market value of assistance to Wisconsin residents.
  • Patients: The bill would not set or cap drug prices, require price cuts, or create or change eligibility for assistance programs. It would require reporting about some price changes and existing assistance programs.
  • DHS and OCI: Both would receive the required notices and reports. DHS would publish the price justifications and carry out the analysis, reporting, and hearing duties; the bill authorizes two additional DHS positions.
  • Public: The proposed public information would include price justifications and DHS’s drug-pricing trends report. The bill does not say that all submitted reports would be published.

Money#

The bill proposes $184,200 for DHS in each of fiscal years 2025–26 and 2026–27, with two additional DHS positions; no full cost estimate is provided in the supplied material.

  • The proposed appropriations total $368,400 across those two fiscal years. The bill does not state the positions’ individual costs or whether the appropriation covers all implementation costs.
  • Manufacturers would face reporting and certification duties, but the bill provides no estimate of their compliance costs.
  • DHS could impose a forfeiture of up to $10,000 per day for a late notice or report. The bill does not state how much would be collected or where the money would go.

What is unclear#

  • The bill does not give a start date or explain when manufacturers’ first notices and reports would be due.
  • It uses existing statutory definitions for “manufacturer” and “pharmacy benefit manager,” but those definition sections are not included in the supplied material, so their full scope cannot be checked here.
  • The bill does not explain how DHS would determine a forfeiture, or whether there would be a process to challenge one.
  • The bill requires DHS to publish price-justification documents but does not describe how it would handle information a manufacturer considers confidential.
  • The supplied material does not establish whether other drug-reporting duties already apply under current Wisconsin law.

Case for#

  • A possible argument for the bill is that advance notice and explanations could give state agencies information about significant price increases and high-cost drug introductions.
  • Reporting price concessions could help DHS examine the difference between wholesale list prices and concessions to pharmacy benefit managers.
  • Reporting on assistance programs could give the state information about their terms and reach among Wisconsin residents.
  • Public reports and hearings could make drug-pricing trends easier for the public to examine.

Case against#

  • The bill requires substantial information from manufacturers, including documents and research related to price decisions, but does not explain how DHS would limit or protect sensitive material before publication.
  • The bill requires reporting but does not give DHS power to approve, block, or change a price. A price increase could still proceed after the required notice.
  • The bill does not set out the process for deciding penalties, and the maximum forfeiture could grow with each day a report is late.
  • The proposed appropriation and two positions may not cover all the work required; the supplied material has no full fiscal estimate.